TAF/EVG Fast Dissolving Vaginal Insert
The Tenofovir alafenamide/ Elvitegravir (TAF/EVG) Fast Dissolving Insert is developed by CONRAD. After extensive end-user research, a TAF/EVG dual-compartment insert for PrEP or PEP user-controlled, on-demand use and Multipurpose Prevention Technology against HIV and HSV, will be advanced clinically, providing a user-friendly on-demand product. This game-changer product leverages positive results in non-human primate models and Phase 1 clinical trials (CONRAD 146; MTN-039) as well as proven efficacy. This product will be optimized for user-informed packaging. Manufacturing scale-up, production of good manufacturing practice supplies and investigational new drug amendment filing support will enable clinical testing in clinical trial networks such as the HPTN and will be prioritized based on opportunities for in-human clinical trials by other funders.